378 related articles for article (PubMed ID: 27481307)
1. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.
Billiet T; Dreesen E; Cleynen I; Wollants WJ; Ferrante M; Van Assche G; Gils A; Vermeire S
Am J Gastroenterol; 2016 Oct; 111(10):1438-1445. PubMed ID: 27481307
[TBL] [Abstract][Full Text] [Related]
2. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
[TBL] [Abstract][Full Text] [Related]
3. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
4. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
[TBL] [Abstract][Full Text] [Related]
5. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type.
Kanis SL; de Lima-Karagiannis A; van der Ent C; Rizopoulos D; van der Woude CJ
J Crohns Colitis; 2018 Jul; 12(8):939-947. PubMed ID: 29771301
[TBL] [Abstract][Full Text] [Related]
7. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients.
Strik AS; Löwenberg M; Buskens CJ; B Gecse K; I Ponsioen C; Bemelman WA; D'Haens GR
Scand J Gastroenterol; 2019 Apr; 54(4):453-458. PubMed ID: 31032686
[No Abstract] [Full Text] [Related]
8. Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.
Liefferinckx C; Minsart C; Toubeau JF; Cremer A; Amininejad L; Quertinmont E; Devière J; Gils A; van Gossum A; Franchimont D
Inflamm Bowel Dis; 2017 Aug; 23(8):1371-1381. PubMed ID: 28498153
[TBL] [Abstract][Full Text] [Related]
9. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.
van Schaik T; Maljaars JP; Roopram RK; Verwey MH; Ipenburg N; Hardwick JC; Veenendaal RA; van der Meulen-de Jong AE
Inflamm Bowel Dis; 2014 Dec; 20(12):2292-8. PubMed ID: 25230167
[TBL] [Abstract][Full Text] [Related]
10. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
[TBL] [Abstract][Full Text] [Related]
11. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter.
Sachs UJ; Socher I; Braeunlich CG; Kroll H; Bein G; Santoso S
Immunology; 2006 Sep; 119(1):83-9. PubMed ID: 16805790
[TBL] [Abstract][Full Text] [Related]
12. Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases.
Grinman AB; de Souza MDGC; Bouskela E; Carvalho ATP; de Souza HSP
Medicine (Baltimore); 2020 Mar; 99(10):e19359. PubMed ID: 32150077
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
[TBL] [Abstract][Full Text] [Related]
14. A
Romero-Cara P; Torres-Moreno D; Pedregosa J; Vílchez JA; García-Simón MS; Ruiz-Merino G; Morán-Sanchez S; Conesa-Zamora P
Int J Med Sci; 2018; 15(1):10-15. PubMed ID: 29333082
[TBL] [Abstract][Full Text] [Related]
15. Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment.
Mechie NC; Mavropoulou E; Ellenrieder V; Kunsch S; Cameron S; Amanzada A
Digestion; 2020; 101(6):761-770. PubMed ID: 31536991
[TBL] [Abstract][Full Text] [Related]
16. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease.
Kim JY; Lee Y; Choe BH; Kang B
Gut Liver; 2021 Jul; 15(4):588-598. PubMed ID: 33024062
[TBL] [Abstract][Full Text] [Related]
17. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
Christensen KR; Steenholdt C; Brynskov J
Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
[TBL] [Abstract][Full Text] [Related]
19. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
20. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]